Compare Erasca Inc. Common Stock (ERAS) vs Sun Life Financial Inc. Common Stock (SLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Erasca Inc. Common Stock vs Sun Life Financial Inc. Common Stock — how do they compare? Erasca Inc. Common Stock trades at $14.6 (market cap $5.17B), while Sun Life Financial Inc. Common Stock trades at $77.62 (market cap $43.10B). The key difference: Sun Life Financial Inc. Common Stock is far larger — about 8.3× Erasca Inc. Common Stock's market cap, and Sun Life Financial Inc. Common Stock pays a 3.48% dividend while Erasca Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Erasca Inc. Common Stock for 1 Days and Sun Life Financial Inc. Common Stock for 0 Days on average.
| ERAS | SLF | |
|---|---|---|
Market Cap | $5.17B | $43.10B |
Volume | 5,313,379 | 448,420 |
Sector | Health | Financials |
52-Week High | $22.47 | $84.07 |
52-Week Low | $2.20 | $57.60 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $4.95B | $44.83B |
Dividend Yield | — | 3.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ERAS trades at $14.78, down 4.4% today, with a bullish technical signal from moving averages and a consensus analyst price target of $22.50. The company is a clinical-stage oncology firm with no revenue, reporting a net loss of $124.55 million in 2025, but holds significant liquidity and has three potential registration-enabling trials ahead. Recent news highlights FDA Fast Track designation for its lead candidate ERAS-0015.
The outlook is speculative, driven by clinical trial progress; upside exists if trials succeed, but high cash burn and shareholder investigations pose substantial risks. Investment hinges on binary outcomes from drug development, making it suitable only for risk-tolerant investors focused on biotech.
Sun Life Financial (SLF) trades at $77.87, up 0.69% on the day, reflecting steady momentum. The stock shows consistent earnings beats in recent quarters, with Q3 2026 results pending. Financial health is solid, with a P/E of 18.82 and robust cash flow projections for 2026. Recent strategic moves include expanding disability benefits and forming a reinsurance partnership, signaling growth initiatives.
The outlook for SLF is cautiously optimistic, supported by earnings strength and strategic expansions. Key risks include competitive pressures and macroeconomic volatility. Analyst sentiment is mixed, with a majority hold rating, suggesting potential stability but limited near-term upside. Investors should weigh solid fundamentals against sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Erasca Inc. Common Stock
Erasca is a biotechnology company developing precision medicines for cancer. Its programs target genetic drivers of tumor growth.
Read more on ERAS →About Sun Life Financial Inc. Common Stock
Sun Life Financial Inc. is a Canada-based financial services company providing insurance, wealth and asset management, and health solutions for individuals and institutions. Its products span life, health, and disability insurance along with mutual funds and pension asset management, through operations in Canada, US, the United Kingdom, Ireland, and across Asia.
Read more on SLF →
